Originally developed as a Dyrk1-targeting drug (351), CX-4945 turned out to be a dual Dyrk-1/GSK-3β inhibitor (352) with a strong modulatory effect on AD-related CaN/NFAT signaling and Tau phosphorylation in the mouse hippocampus. The gene discussed is MAPT; the disease is Alzheimer disease.